Syncona Biotechs Face Up To Trial Delays Over COVID-19
Programs Put Back 'At Least Three Months'
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
